Wednesday 7/11 Insider Buying Report: VTVT, DERM Wednesday, July 11, 10:35 AM ET
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At vTv Therapeutics (VTVT), a filing with the SEC revealed that on Friday, Ronald O. Perelman bought 570,776 shares of VTVT, at a cost of $4.38 each, for a total investment of $2.5M. Investors have the opportunity to buy VTVT at a price even lower than Perelman did, with shares changing hands as low as $1.46 at last check today which is 66.7% under Perelman's purchase price. vTv Therapeutics is trading up about 2.8% on the day Wednesday. Before this latest buy, Perelman purchased VTVT at 5 other times during the past twelve months, for a total cost of $929,551 at an average of $4.32 per share.
And at Dermira (DERM), there was insider buying on Monday, by CEO & Chairman of the Board Thomas G. Wiggans who purchased 12,000 shares at a cost of $10.00 each, for a total investment of $119,951. Before this latest buy, Wiggans purchased DERM at 2 other times during the past year, for a total investment of $239,584 at an average of $9.24 per share. Dermira Inc is trading off about 1.4% on the day Wednesday. Wiggans was up about 9.4% on the buy at the high point of today's trading session, with DERM trading as high as $10.94 in trading on Wednesday.
For MarketNewsVideo.com, I'm Sayoko Murase.
|